Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
76 hedge funds and large institutions have $116M invested in Agile Therapeutics in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 22 increasing their positions, 15 reducing their positions, and 10 closing their positions.
200% more call options, than puts
Call options by funds: $641K | Put options by funds: $214K
47% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 15
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
1% more funds holding
Funds holding: 75 → 76 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less capital invested
Capital invested by funds: $118M → $116M (-$2.06M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$2.05M |
| 2 |
NIM
Needham Investment Management
New York
|
+$1.77M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.64M |
| 4 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
+$612K |
| 5 |
Two Sigma Investments
New York
|
+$506K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DG Capital Management
New York
|
-$2.55M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$693K |
| 3 |
SG Americas Securities
New York
|
-$423K |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$212K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$177K |
AGRX Hedge Fund Activity: Q4 2020 in Review
76 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q4 2020, worth a combined $116M — down 1.7% from $118M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new AGRX positions and 10 closed out — a net gain of 1 holder — while 22 added to existing stakes and 15 trimmed.
The largest buyer was Manulife (Manufacturers Life Insurance), adding an estimated $2.05M. The largest seller was DG Capital Management, cutting an estimated $2.55M.
- 76 institutional investors held Agile Therapeutics (AGRX) as of Q4 2020, up from 75 in Q3 2020.
- Funds reported $116M of Agile Therapeutics stock for Q4 2020, down 1.7% quarter-over-quarter.
- 11 funds opened new Agile Therapeutics positions in Q4 2020 and 10 closed out, a net change of +1 holder.
- The largest Agile Therapeutics buyer in Q4 2020 was Manulife (Manufacturers Life Insurance), an estimated $2.05M added.
- The largest Agile Therapeutics seller in Q4 2020 was DG Capital Management, an estimated $2.55M sold.
Based on aggregated 13F filings for Q4 2020.